Susan Granato
Nurse Practitioner · Bethesda, MDNPI 1225688427
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.9%), other and consulting fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Novartis at 37.1% of the total. 2025 is the largest year on record at $3,916, more than ten times the $163 reported in 2022. Among nurse practitioner clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 107 payments — averaging $50.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Pharmacosmos Therapeutics Inc.$679
- Beone Medicines USA, Inc.$243
- Incyte Corporation$216
- Johnson & Johnson$206
- Pharmaessentia USA Corporation$182
- plus $2K from 30 others
What the payments were for
- Consulting fees$74014%
- Speaking & faculty fees$60011%
- Food & beverage$2,93554%
- Education$771%
- Other$1,09720%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $2,020 |
| Pharmacosmos Therapeutics Inc. | 3 | $679 |
| Beone Medicines USA, Inc. | 5 | $243 |
| Incyte Corporation | 6 | $216 |
| Johnson & Johnson | 9 | $206 |
| Pharmaessentia USA Corporation | 6 | $182 |
| Fennec Pharmaceuticals, Inc. | 1 | $172 |
| Puma Biotechnology, Inc. | 2 | $148 |
| Merck | 6 | $140 |
| Pfizer | 5 | $136 |
| AstraZeneca(2 entities) | 4 | $122 |
| Sanofi | 1 | $114 |
| Sobi, Inc | 4 | $96 |
| Regeneron Healthcare Solutions, Inc. | 3 | $95 |
| Janssen Scientific Affairs, LLC | 1 | $83 |
| GSK | 3 | $78 |
| AbbVie | 3 | $69 |
| E.r. Squibb & Sons, L.L.C. | 2 | $66 |
| Blueprint Medicines Corporation | 2 | $63 |
| Syndax Pharmaceuticals, Inc. | 2 | $54 |
| Caris MPI, Inc. | 2 | $48 |
| ADC Therapeutics America, Inc. | 2 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Mirati Therapeutics, Inc. | 1 | $35 |
| Eisai Inc. | 1 | $28 |
| Celltrion USA Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Array Biopharma Inc | 1 | $25 |
| Corcept Therapeutics | 1 | $24 |
| Spectrum Pharmaceuticals Inc. | 1 | $23 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,449 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 23 | $15,988 |
| Hydroxyurea | 18 | $517 |
| Dexamethasone | 17 | $471 |
| Prochlorperazine Maleate | 16 | $284 |
| Ondansetron Hcl | 21 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $136 | $15,98823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,562 nurse practitioner providers in Maryland.
Other nurse practitioner in Bethesda
- Francesca van SantBethesda$16K
- Diane HearnBethesda$7K
- Elizabeth SmithBethesda$6K
- Morgan GaleRockville$292K
- Sherilyn BrinkleyBaltimore$100K
- Michelle TurnerBaltimore$94K
- Nelli ZafmanLutherville$67K
- Ellen LancasterFallston$52K
- Doris TateEaston$34K
- Zeev NemirovskyBaltimore$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.